Contributed by Justin Miller, Bowman Lab Alzheimer’s disease (AD), a dementia characterized by loss of memory and cognitive abilities, afflicts over an estimated 44 million people worldwide. While recent clinical…
Read moreWe are continuing our work with AD in terms of repurposing an existing drug against the leads we have found from Folding@home. The benefit of this approach is that this…
Read moreWe’re very excited to report on our progress towards our goal to develop new small molecule drug candidates for AD. In a paper just published in the Journal of Medicinal…
Read moreWe have been working closely with the Nanomedicine Center for Protein Folding on pushing our lead compounds forward. They have gone from the test tube to the first round of…
Read moreWe have had some exciting results regarding new possible drug leads for Alzheimer’s. We hope to be submitting these soon for publication.
Read moreWe presented our results regarding new possible drugs (small molecule leads) to fight Alzheimer’s Disease at a recent meeting at Stanford, supported by the NIH Roadmap Nanomedicine center and NIH…
Read moreThe first of the papers has come out (see paper #58 on our Results page: “Simulating oligomerization at experimental concentrations and long timescales: A Markov state model approach”). In many…
Read moreWe have made some significant progress experimentally testing our computational predictions using nuclear magnetic resonance spectroscopy (NMR).
Read moreWe have submitted our first paper for peer review and we’re working on the next 2 paper right now. We’re very excited about the results!
Read moreProf. Vijay Pande presented recent FAH work on AD at the National Parkinson’s Foundation conference (in the session on AD and its connections to PD).
Read more